Illumina Stock News

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Ligand Pharmaceuticals (LGND) and Illumina (ILMN). But which of these two companies is the best opti

#Morningstar #StockMarket #Investing Plus our take on Nvidia stock and our market outlook for June. Read more from David Sekera here: https://www.morningstar.com/stocks/2-undervalued-medtech-stocks-op

Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.

Illumina is undervalued by 23% according to a discounted cash flow analysis, with a fair value of $253.94. The company aims to expand into the $120bn TAM industries of oncology testing, genetic diseas

At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.

Billionaire investor Carl Icahn (Trades, Portfolio) disclosed his firm's first-quarter equity portfolio earlier this month.

Illumina Inc. ILMN, -12.05% shareholders voted Thursday to elect one of activist investor Carl Icahn's nominees to its board, and voted against the re-election of company Chairman John Thompson, accor

Carl Icahn has accused Illumina's management and board of poor oversight, particularly with regard to the company's acquisition of cancer test maker Grail.

ILMN trades at a higher valuation of 7.3x trailing revenues, compared to 4.6x for TMO, partly due to its financial position.

Activist investor Carl Icahn is seeking to unseat Illumina's chairman and its CEO, and put three of his own people on the company's board.

Despite a short seller's accusations that his company has inflated its asset prices, Carl Icahn's effort to shake up Illumina's board is still very much in the interest of shareholders.

The legendary activist, whose own company is under attack, has launched a proxy contest for three seats on the gene-sequencing giant's board, which is mired in a messy acquisition. The stakes are high

Carl Icahn (Trades, Portfolio) is one of the most iconic activist investors or “corporate raiders” that has ever existed. Despite being 87 years old, he is still very active in the market.

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader.

Illumina announced a downbeat set of earnings for its fiscal 2023 first quarter. The company received more than 200 orders for its new NovaSeq X instrument from customers in almost 30 countries.